Reply to Letter: HbA1c/C-Peptide Ratio is a Potential Biomarker Used to Predict No-Reflow Phenomenon in Patients With ST-Elevation Myocardial Infarction
Restricted accessLetterFirst published online March, 2025
Reply to Letter: HbA1c/C-Peptide Ratio is a Potential Biomarker Used to Predict No-Reflow Phenomenon in Patients With ST-Elevation Myocardial Infarction
MoDGWangMM. HbA1c/C-Peptide ratio is a potential biomarker used to predict No-reflow phenomenon in patients with ST-elevation myocardial infarction. Angiology. 2025;76:300-301.
2.
ToprakKKaplangorayMMemioğluT, et al.The HbA1c/C-peptide ratio is associated with the No-reflow phenomenon in patients with ST-elevation myocardial infarction. Angiology. 2025;76:289-299.
3.
GalassoGSchiekoferSD’AnnaC, et al.No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology. 2014;65:180-189.
4.
ToprakKKaplangorayMAkyolS, et al.The non-HDL-C/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction. Acta Cardiol. 2024;1-12.
5.
KaplangorayMToprakKAydınC, et al.Investigation of the relationship between modified Glasgow prognostic score and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. The European Research Journal. 2023;9:894-902.
6.
KaplangorayMToprakKCicekOF, et al.Relationship between the fibrinogen/albumin ratio and microvascular perfusion in patients undergoing primary percutaneous coronary intervention for ST-elevated myocardial infarction: a prospective study. Arq Bras Cardiol. 2023;120:e20230002.
7.
ToprakK. Effect of serum C-peptide levels on the development of contrast-induced nephropathy in diabetic patients undergoing coronary angiography. Angiology. 2024;75:139-147.
8.
ToprakKKaplangorayMPaliceA. The impact of C-peptide and diabetes mellitus on coronary ectasia and effect of coronary ectasia and C-peptide on long-term outcomes: a retrospective cohort study. Int J Clin Pract. 2022;2022:7910566.
9.
ToprakKKaplangörayMMemioğluT, et al.HbA1c/C-peptide ratio is associated with angiographic thrombus burden and short-term mortality in patients presenting with ST-elevation myocardial infarction. Blood Coagul Fibrinolysis. 2023;34:302-303.
10.
ToprakKKaplangorayMInanırMMemioğluT. How effective is the systemic inflammatory immune index in the etiopathogenesis of isolated coronary artery Ectasia?Reply. Arq Bras Cardiol. 2023;120:e20230048.
11.
ToprakKKaplangörayMMemiogluTİnanirM. Is the predictive value of systemic immune-inflammation index superior to traditional markers in ST-elevation myocardial infarction patients?Coron Artery Dis. 2023;34:281.
12.
ToprakKYılmazRKaplangorayM, et al. Comparison of the effect of uric acid/albumin ratio on coronary colleteral circulation with other inflammation-based markers in stable coronary artery disease patients. Perfusion. 2024;39:1440-1452.
13.
ToprakKÖzenKMemioğluT, et al. Comparison of the effect of uric acid/albumin ratio on coronary slow flow with other inflammation-based markers. Biomarkers Med. 2024;18:25-37.
14.
Hajian-TilakiK. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013;4:627-635.
